May 11, 2023
- May 10, 2024

The Advancing Role of PARP Inhibitor Combination Therapies to Improve Outcomes for Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC)

EARNed Credits

1.0

AMA PRA Category 1 CreditTM

1c798d84791d98e3324393060e3471ae

Overview

This CME program, derived from content presented at the AACR Annual Meeting 2023 in Orlando, FL, will highlight the advancing role of PARP inhibitor combination therapies to improve outcomes for patients with metastatic castration-resistant prostate cancer (mCRPC). The expert faculty, led by Dr. Alan Tan, will first review the science, mechanism of action, and clinical rationale for PARP-inhibitors and PARP-inhibitor/androgen receptor combinations to treat patients with mCRPC. Next, an analysis of current clinical trial data and clinical applications for new and emerging therapies, including PARP-inhibitors combined with androgen receptor targeted therapies, will be discussed. Following, the faculty will assess the evolving paradigm of potential treatment strategies and patient adherence factors for PARP inhibitor combinations to improve outcomes in patients with mCRPC. Upon completion of this activity, learners will gain better insight into how to treat their patients with metastatic castration-resistant prostate cancer (mCRPC) utilizing PARP inhibitor combination therapies.

Who Should Attend

Oncologists and all other healthcare professionals involved in the treatment of prostate cancer

Provided By

Course Faculty

Alan Tan, MD
Director of Genitourinary Oncology Rush University Medical Center Executive Officer, Alliance for Clinical Trials in Oncology Chicago, IL
Alan H. Bryce, MD
Professor of Medicine Mayo Clinic Phoenix, AZ
Maha Hussain, MD
Genevieve Teuton Professor of Medicine Deputy Director, Robert H. Lurie Comprehensive Cancer Center Chicago, IL

Learning Objectives

1

Review the science, mechanism of action and clinical rationale for PARP-inhibitors and PARP-inhibitor/androgen receptor combinations to treat patients with mCRPC

2

Analyze current clinical trial data and clinical applications for new and emerging therapies, including PARP-inhibitors combined with androgen receptor targeted therapies

3

Review the evolving paradigm of potential treatment strategies and patient adherence factors for PARP inhibitor combinations to improve outcomes in patients with mCRPC

Additional Course Information

It is the policy of AcademicCME that all faculty, instructors, and planners disclose relevant financial relationships relating to the topics of this educational activity. Any relevant financial relationships are mitigated via a content review by planning committee members and faculty with no relevant financial relationships.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:

Faculty Relationship Identified With:
Alan Tan, MD (Course Chair) Consultant/Advisor: Bristol Myers Squibb; EMD Serono; Exelixis; Foundation Medicine; Gilead; Merck; Myovant; Natera

Equity: Adaptimune; Bluebird; Editas; Fate Therapeutics; Iovance; Jounce Therapeutics; MEI Pharma; Mirati; Natera

Alan Bryce, MD Consultant/AdvisorAstraZeneca; Bayer; Janssen; Merck; Myovant; Pfizer Inc.

Grant/Research Support: Janssen

Maha Hussain, MD Consultant/AdvisorAstraZeneca; Bayer; Convergent; GlaxoSmithKline; Janssen; Novartis; Pfizer Inc.

Grant/Research Support: AstraZeneca; Arvinas; Bayer; Genentech

Timothy Hayes, MD, PhD; Kim Cheramie, MSN, RN-BC; Chelsey Simonds and Nicole McMenamin hereby state that they or their spouse/life partner do not have any relevant financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.

In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

AcademicCME designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit TM.

Clinicians should claim only the credit commensurate with the extent of their participation in the activity.

This activity has been supported by an independent educational grant from Pfizer Inc.

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and Pfizer Inc. do not recommend the use of any agent outside of the labeled indications.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

In order to claim credit, participants must complete the following:

  1. Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
  2. Complete the Pre-Activity Questions
  3. Read or Review the activity content.
  4. Complete the Post-Activity Test Questions and Evaluation.
  5. Learners who receive a grade of 60% or better on the Post-Activity Test Questions and complete the Evaluation will receive appropriate credit as indicated (CME, CNE, and/or CPE credit).
  • CME and CNE credit will be issued appropriate certificate of completion.
  • Others may request a “certificate of completion”.
  1. Learners should claim only the credit commensurate with the extent of their participation in the activity.

For all CE inquiries or special needs, please contact [email protected].

May 11, 2023
- May 10, 2024

The Advancing Role of PARP Inhibitor Combination Therapies to Improve Outcomes for Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Related Webcast Courses

Oncology
CAR T Research and Treatment Advances in Chronic Lymphocytic Leukemia (CLL), Mantle Cell L...
Oncology
Utilizing Immunohistochemistry Testing, Biomarkers, and Targeted Therapeutics to Optimize ...
Oncology
Applying Poly (ADP-ribose) Polymerase (PARP) Inhibitors to Maintenance Treatment Plans to ...